Giredestrant

CAS No. 1953133-47-5

Giredestrant( GDC-9545 )

Catalog No. M23885 CAS No. 1953133-47-5

Giredestrant potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain.?Giredestrant has anti-tumor activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 210 In Stock
5MG 260 In Stock
10MG 417 In Stock
25MG 785 In Stock
50MG 1251 In Stock
100MG 1962 In Stock
200MG 2673 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Giredestrant
  • Note
    Research use only, not for human use.
  • Brief Description
    Giredestrant potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain.?Giredestrant has anti-tumor activity.
  • Description
    Giredestrant potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain.?Giredestrant has anti-tumor activity.?Giredestrant, a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist.?
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    GDC-9545
  • Pathway
    Endocrinology/Hormones
  • Target
    Estrogen Receptor/ERR
  • Recptor
    ER
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1953133-47-5
  • Formula Weight
    522.55
  • Molecular Formula
    C27H31F5N4O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:100mg/mL (191.37 mM; Need ultrasonic)
  • SMILES
    C[C@H](Cc1c2[nH]c3c1cccc3)N(CC(CO)(F)F)[C@@H]2c(c(F)cc(NC1CN(CCCF)C1)c1)c1F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.C Metcalfe, et al. Abstract P5-04-07: GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes
molnova catalog
related products
  • (R)-Equol

    (R)-Equol is an ERα and ERβ agonist with Kis of 27.4 and 15.4 nM, respectively.

  • Coumestrol

    Coumestrol that existed in soybean products suppresses the proliferation of ES2 cells (IC50: 50 μM).

  • Palazestrant

    Palazestrant (OP-1250) is an orally available and highly potent estrogen receptor antagonist and selective ER degrader with antitumor activity.